Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682228 | 0.87 | L3MBTL1 (0.52) | ALDH1A1TDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6611902 | 0.84 | GPBAR1 (0.34) | MAPK8KDM4E | |
| SCHEMBL5357847 | 0.83 | PTGER4 (0.38) | CYP2C9TDP1 | |
| SCHEMBL5359315 | 0.82 | PTGER4 (0.39) | MAPK8KDM4E | |
| SCHEMBL5365077 | 0.82 | MAPK8 (0.56) | MAPK8SMN1; SMN2 | |
| SCHEMBL5364869 | 0.81 | MAPK8 (0.52) | MAPK8ALDH1A1KDM4E | |
| SCHEMBL5358857 | 0.80 | MAPK8 (0.53) | MAPK8SMN1; SMN2 | |
| SCHEMBL5362092 | 0.79 | MAPK8 (0.52) | MAPK8SMN1; SMN2 | |
| SCHEMBL6474578 | 0.78 | P2RX7 (0.33) | ALDH1A1KDM4E | |
| SCHEMBL5361468 | 0.78 | MAPK8 (0.51) | MAPK8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-6953810-B2 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-10-11 | — | — | US | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2004-03-11 | — | — | US | disclosed |
| US-6649633-B2 | For treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-11-18 | — | — | US | disclosed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | MAPK8 3111/4885ALDH1A1 607/4885CYP2C9 1587/4885 |
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, PDE4A, NOX1 | MAPK8 2655/4885ALDH1A1 416/4885CYP2C9 1824/4885 |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, NOX1, NOX4 | MAPK8 2943/4885ALDH1A1 457/4885CYP2C9 1685/4885 |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | MAPK8 3287/4885ALDH1A1 584/4885CYP2C9 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.